Drug Science is the leading independent scientific body on drugs in the UK. We work to provide clear, evidence-based information without political or commercial interference.

Get Project Twenty21 Updates via Email It’s been a very busy start to the year, with lots of change happening and expansion in the pipeline for the project - so there's so much to update you on. We've got loads of events coming up, so scroll down to get them in…

By Dr Carol Routledge, Chief Medical & Scientific Officer at Small Pharma DMT-assisted therapy is a novel psychedelic therapy which aims to treat a whole suite of mental health problems that we have sadly come to take for granted as part of 21st century life. Early trials are investigating DMT-assisted therapy…

DHSC announces that it will not legalise the world’s most successful smoking substitute   The health department has stated that it will not legalise the oral nicotine product snus The product has driven the world’s most dramatic falls in smoking in Scandinavia It is popular among hardcore smokers who do not…

7th February 2021 Drug Science’s large scale observational study of medical cannabis has opened its first non-UK operation in Australia Known as Project Twenty21 Australia, it will be run in collaboration with the Australasian College of Cannabinoid Medicine (also known as ACCM, and the research arm of Releaf Group Ltd).  …

Medical cannabis is fast becoming a frequently asked about topic between patients and GPs in the UK, as demonstrated by the Primary Care Cannabis Network’s 2021 Survey which spoke to over 1000 GPs about their attitudes towards cannabis-based medicines: the survey found that more than two-thirds of GPs in the UK…

Authors Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill, David J Nutt Published February 3, 2022 Psychedelic medicines are a rapidly developing area of clinical research and public health policy. Despite an increasing body of studies highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs…